小胸腺瘤无肌无力患者剑突下胸腔镜胸腺切除术后当日出院的前瞻性单臂临床试验
本研究为单臂、单中心前瞻性临床试验,评估剑突下胸腔镜胸腺切除术后当日出院(SDD)的安全性与可行性。结论认为SDD可能安全可行,但样本量小,需大规模研究确认。
要点
- 剑突下胸腔镜胸腺切除术后当日出院完成率92.3%(36/39)。
- 围术期并发症率5.6%(2/36),30天内再入院率2.8%(1/36)。
核心结论
- 对于经过选择的剑突下胸腔镜胸腺切除术患者,当日出院程序可能安全可行,但基于小样本量,需大规模研究确认。
研究设计与样本
- 单臂、单中心前瞻性临床试验,注册号ChiCTR2300077148,纳入39例术前临床诊断胸腺肿瘤患者。
主要发现
- 所有患者均实现R0切除。
- SDD完成率为92.3%(36/39)。
- 围术期并发症率为5.6%(2/36)。
- 仅2.8%(1/36)的患者因气胸在1个月内急诊就诊后再入院。
临床怎么用
- 对于小胸腺瘤且无肌无力患者,剑突下胸腔镜胸腺切除术后可考虑当日出院,但需严格选择患者并做好围术期评估。
局限性
- 样本量小(39例),为单臂单中心研究,需大规模研究确认初步发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Subxiphoid thoracoscopic surgery is an effective method for treating thymic tumours. We performed the first evaluation of the safety and feasibility of same-day discharge (SDD) in patients undergoing this procedure and summarized their associated clinical experience. METHODS: We conducted a single-arm, single-centre prospective clinical trial. This study was registered at www.chictr.org.cn (ChiCTR2300077148). The subjects were patients with a preoperative clinical diagnosis of thymic tumour. All eligible patients underwent examinations and preparations at the preoperative preparation centre and subsequently underwent a subxiphoid thoracoscopic thymectomy. The evaluation indicators included R0 (complete resection without residual tumour) resection rate, SDD completion rate, 30-day postoperative readmission rate, number of emergency visits, perioperative complication rate, length of stay and total medical costs. RESULTS: A total of 39 patients were enrolled between November 2023 and April 2024. All patients underwent subxiphoid thoracoscopic resection of the thymic tumours to achieve R0 resection. The completion rate of the SDD surgery was 92.3% (36/39). The perioperative complication rate was 5.6% (2/36 patients). Only 2.8% (1/36) of the patients were readmitted within 1 month of an emergency visit due to pneumothorax. The median length of stay was 11 h (interquartile range 10-14), and the median total medical cost was 19 400 renminbi (interquartile range 18 500-21 100). CONCLUSIONS: The SDD procedure may be safe and feasible for selected patients undergoing subxiphoid thoracoscopic thymectomy, based on a small sample size. Large-scale studies are needed to confirm these preliminary findings.
引用
- Zheng YL, Yuan YP, Liang XY, et al. Same-day discharge for patients undergoing subxiphoid thoracoscopic thymectomy for small tumours without myasthenia gravis: a prospective, single-arm clinical trial. Eur J Cardiothorac Surg. 2025. PMID: 40172929. doi:10.1093/ejcts/ezaf122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。